The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and her2 expression in invasive breast cancer: A prospective study

American Journal of Surgical Pathology

Volumn 35, Issue 4, 2011, Pages 545-552

  Tong, Leung Chu ^a   Nelson, Nahid ^b   Tsourigiannis, Jim ^b   Mulligan, Anna Marie ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Breast cancer; fixation; HER2; hormone receptors; immunohistochemistry

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LYMPH NODE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROSPECTIVE STUDY; TIME; TISSUE FIXATION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TISSUE FIXATION;

EID: 79953174322     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31820e6237     Document Type: Article

References (58)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
2. Allegra JC, Lippman ME, Simon R, et al. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treatment Reports. 1979;63:1271-1277. (Pubitemid 10187969)
3. Allred DC Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist. 2008;13:1134-1136.
4. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168. (Pubitemid 28144151)
5. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7(suppl 6):S1-S21. quiz S22-23.
6. Arber DA. Effect of prolonged formalin fixation on the immuno-histochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol. 2002;10:183-186. (Pubitemid 34553177)
7. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332-4337. (Pubitemid 20225674)
8. Centeno JA, O'Leary TJ. Interactions of short-chain alcohols with dimyristoylphosphatidylethanolamine bilayers: a calorimetric and infrared spectroscopic investigation. Biochemistry. 1990;29:7289-7296. (Pubitemid 20230059)
9. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123:16-20. (Pubitemid 40066167)
10. Crowe JP, Hubay CA, Pearson OH, et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat. 1982;2:171-176. (Pubitemid 13233534)
11. DeLellis RA. Variability in achieving reproducible results in diagnostic immunohistochemistry laboratories. Hum Pathol. 1994; 25:1109-1110.
12. Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK. J Clin Pathol. 2000;53:890-892.
13. Ellis IO, Bartlett J, Dowsett M, et al. Best Practice No 176: updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004; 57:233-237. (Pubitemid 38338829)
14. Esteban JM, Ahn C, Battifora H, et al. Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am J Clin Pathol. 1994;102:S9-S12. (Pubitemid 24345578)
15. Fisher ER, Anderson S, Dean S, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer. 2005;103:164-173. (Pubitemid 39665470)
16. Fox CH, Johnson FB, Whiting J, et al. Formaldehyde fixation. J Histochem Cytochem. 1985;33:845-853.
17. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569-1583. (Pubitemid 41511089)
18. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120: 86-92. (Pubitemid 37046374)
19. Goldstein NS, Hewitt SM, Taylor CR, et al. Recommendations for improved standardization of immunohistochemistry. Appl Immuno-histochem Mol Morphol. 2007;15:124-133. (Pubitemid 46828218)
20. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol. 2000;11:647-663.
21. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907-922.
22. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28:2784-2795.
23. Hanna W, O'Malley FP, Barnes P, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol. 2007;14:149-153.
24. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481. (Pubitemid 29220854)
25. Helander KG. Kinetic studies of formaldehyde binding in tissue. Biotech Histochem. 1994;69:177-179. (Pubitemid 24163542)
26. Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?. J Clin Oncol. 2007;25: 611-613. (Pubitemid 350002913)
27. Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22:1457-1467.
28. Knight WA, Livingston RB, Gregory EJ, et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977;37:4669-4671. (Pubitemid 8239679)
29. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treat-ment: the M77001 study group. J Clin Oncol. 2005;23:4265-4274. (Pubitemid 46207001)
30. Maxwell P, McCluggage WG. Audit and internal quality control in immunohistochemistry. J Clin Pathol. 2000;53:929-932.
31. Mengel M, Hebel K, Kreipe H, et al. Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer. Breast J. 2005;11: 34-40. (Pubitemid 40209342)
32. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545-1554. (Pubitemid 39627082)
33. Nicholson RI, Campbell FC, Blamey RW, et al. Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem. 1981;15: 193-199. (Pubitemid 12069239)
34. O'Leary TJ. Standardization in immunohistochemistry. Appl Immunohistochem Mol Morphol. 2001;9:3-8. (Pubitemid 32179102)
35. Osoba D, Slamon DJ, Burchmore M, et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002;20:3106-3113. (Pubitemid 34791100)
36. Oyama T, Ishikawa Y, Hayashi M, et al. The effects of fixation, processing and evaluation criteria on immunohistochemical detec-tion of hormone receptors in breast cancer. Breast Cancer (Tokyo, Japan). 2007;14:182-188.
37. Parkes HC, Lillycrop K, Howell A, et al. C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer. 1990;61:39-45. (Pubitemid 20043541)
38. Reynolds GJ. External quality assurance and assessment in immunocytochemistry. Histopathology. 1989;15:627-633. (Pubitemid 20022912)
39. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohis-tochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evalua-tion of scoring systems. J Clin Pathol. 2000;53:125-130. (Pubitemid 30075056)
40. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684. (Pubitemid 41464706)
41. Rudiger T, Hofler H, Muller-Hermelink HK. Immunohistochem-istry Circle Trial of the University Institute of Pathology [in Germany]. Der Pathologe. 1997;18:262-268. (Pubitemid 27267287)
42. Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol. 2001;25:1204-1207. (Pubitemid 32777722)
43. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY. 1987;235:177-182. (Pubitemid 17231334)
44. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, NY). 1989;244:707-712. (Pubitemid 19147683)
45. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
46. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36. (Pubitemid 46039831)
47. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastu-zumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811-7819. (Pubitemid 46657378)
48. Taylor CR. An exaltation of experts: concerted efforts in the standardization of immunohistochemistry. Hum Pathol. 1994;25: 2-11.
49. Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525-3533. (Pubitemid 47310891)
50. Von Wasielewski R, Mengel M, Nolte M, et al. Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J. 1998;4:33-40. (Pubitemid 28080204)
51. Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008;61:818-824. (Pubitemid 351969725)
52. Walt AJ, Singhakowinta A, Brooks SC, et al. The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery. 1976;80:506-512.
53. Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluor-escence in situ hybridisation assays. J Clin Pathol. 2000;53:374-381. (Pubitemid 30256906)
54. Werner M, Chott A, Fabiano A, et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24:1016-1019. (Pubitemid 30430490)
55. Westerberg H, Gustafson SA, Nordenskjold B, et al. Estrogen receptor level and other factors in early recurrence of breast cancer. Int J Cancer. 1980;26:429-433. (Pubitemid 10005821)
56. Wick MR, Mills SE. Consensual interpretive guidelines for diagnostic immunohistochemistry. Am J Surg Pathol. 2001;25: 1208-1210. (Pubitemid 32777723)
57. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
58. Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommenda-tions on estrogen receptor testing in breast cancer by immunohis-tochemistry. Appl Immunohistochem Mol Morphol. 2008;16:513-520.